Novartis to buy breast cancer drug candidate from Synnovation
Novartis is set to acquire a promising breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, strengthening its oncology pipeline. The experimental therapy targets HR-positive/HER2-negative breast cancer using a next-generation PI3Kα inhibition approach.
Ludwig Burger/Reuters
March 20, 2026
FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020.
Arnd Wiegmann/Reuters
Novartis NOVN.S said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achievements.
The experimental drug belongs to the class of selective PI3Kα inhibitors, a new approach for the treatment of a type of breast cancer known as HR positive/HER2 negative and potentially other solid tumours.
-Ludwig Burger/Reuters
TOP HEALTH STORIES
WHO chief to meet Congo president, as aid group warns Ebola likely spread undetected for months
Ebola recoveries bring signs of hope in DRC as suspected cases emerge outside Africa
Prostate cancer drug reduces risk of cancer spread and death in late-stage study
LATEST NEWS
53 rescuers work together to save man stuck in deep Italian cave
Israel's Netanyahu orders attacks in Beirut's southern suburbs
Five dead, two injured in fire at Hanwha Aerospace plant in South Korea
GET IN TOUCH
desk@myparaluman.ph
Tektite Towers (East), Exchange Road
Ortigas Center. San Antonio 1600
City of Pasig, NCR, Philippines
+63284298877
MENU
© 2026 Paraluman News Publication